(Q40944821)

25 September 2017

1 reference

title

Hormone therapy for prostate cancer: a topical perspective (English)

1 reference

25 September 2017

Klein EA

1

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

25 September 2017

1 reference

25 September 2017

volume

47

1 reference

25 September 2017

issue

1A Suppl

1 reference

25 September 2017

page(s)

3-12; discussion 29-32

1 reference

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Antiandrogens alone or in combination for treatment of prostate cancer: the European experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Proceedings: The natural history of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Chemoprevention of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Prostatic intraepithelial neoplasia: a premalignant lesion

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Radical prostatectomy for high grade disease: a reevaluation 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

Androgen receptor alterations in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980002-1

7 January 2021

10.1016/S0090-4295(96)80002-1

Identifiers

DOI

1 reference

25 September 2017

1 reference